Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair DeficiencyÉric Bouffet, Uri Tabori, Michael Osborn et al.|Journal of Clinical Oncology|2016Cited by 867
<i>GFAP</i> mutations, age at onset, and clinical subtypes in Alexander diseaseMorgan J. Prust, Adeline Vanderver, Jiaxian Wang et al.|Neurology|2011Cited by 256
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromasBrigitte C. Widemann, Frank M. Balis, Eva Dombi et al.|Neuro-Oncology|2014Cited by 114
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human CellsJiil Chung, Cynthia Hawkins, Yosef E. Maruvka et al.|Cancer Discovery|2020Cited by 85
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J. Ullrich, Mark W. Kieran, Sanjay P. Prabhu et al.|Neuro-Oncology|2020Cited by 82